In T-DLBCL, the overall beneficial role of TILs and PD-L1+ TAMs was shown to be especially evident among immunochemotherapy-treated patients and can therefore relate to the crucial role of host immunity and the pre-existing TIL and TAM populations that can induce a response to both chemotherapy agents and rituximab. This evidence concerns the gene CD274 and diffuse large B-cell lymphoma.